Certified by Founder
Lodge
Indapta Therapeutics
start up
United States
- Seattle & Houston
- 18/12/2024
- Unknown
- $22,500,000
Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
- Industry Biotechnology
- Website https://indapta.com/
- LinkedIn https://www.linkedin.com/company/indapta-therapuetics/
Ciphero | $2,500,000 | (Dec 23, 2025)
beycome | $2,500,000 | (Dec 23, 2025)
Givefront | $2,000,000 | (Dec 23, 2025)
StretchSense | $2,300,000 | (Dec 23, 2025)
ZeroPhase | $6,800,000 | (Dec 23, 2025)
Peripheral Labs | $3,600,000 | (Dec 23, 2025)
Ethereal Exploration Guild | $21,000,000 | (Dec 23, 2025)
LatentForce | $1,700,000 | (Dec 23, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Amphix Bio | $12,500,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)